Therapy News and Research

RSS

HDAC inhibitors flush latent HIV infection from hiding

A team of researchers at the University of North Carolina at Chapel Hill have successfully flushed latent HIV infection from hiding, with a drug used to treat certain types of lymphoma.

9 Mar 2012

U.S. Physical Therapy fourth quarter net revenues increase 13.8% to $60,678,000

U.S. Physical Therapy, Inc., a national operator of outpatient physical therapy clinics, today reported results for the fourth quarter and year ended December 31, 2011.

9 Mar 2012

New hybrid aspirin shrinks tumors, curbs cancer cell growth

The humble aspirin may soon have a new role. Scientists from The City College of New York have developed a new aspirin compound that has great promise to be, not only an extremely potent cancer-fighter, but even safer than the classic medicine cabinet staple.

9 Mar 2012

NCCN issues new guidelines for AYA oncology patients

The National Comprehensive Cancer Network announces that it has issued new NCCN Clinical Practice Guidelines in Oncology for Adolescent and Young Adult (AYA) Oncology. AYA patients are defined in the guidelines as individuals 15 to 39 years of age at initial cancer diagnosis.

9 Mar 2012

Estrogen only HRT in some postmenopausal women could lower breast cancer risk: Study

...

8 Mar 2012

Surgical intervention can be life-restoring for people with intractable temporal lobe epilepsy

While the thought of any type of surgery can be disconcerting, the thought of brain surgery can be downright frightening. But for people with a particular form of epilepsy, surgical intervention can literally be life-restoring.

8 Mar 2012

Positive phase II trial results from Circassia's ragweed allergy therapy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.

8 Mar 2012

Symposium to cover latest breakthroughs in percutaneous treatment of CAD

The agenda for the Optimizing PCI Outcomes: A Vision for 2012 symposium is now available at: http://www.pcioutcomes.com/conference/agenda.html. This evening symposium will feature the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease, including the latest clinical data on current and second-generation drug-eluting stent device-based therapies.

8 Mar 2012

MRF clinical trial to examine antigen-specific MS therapy

The Myelin Repair Foundation (MRF) announced today that its research might soon lead into a clinical proof-of-concept trial at the Department of Neuroimmunology and Multiple Sclerosis Research (nims), University Hospital Zürich, Switzerland, and the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research (inims) in Hamburg, Germany.

8 Mar 2012

Metformin drug appears to prevent growth of atherosclerosis in patients with HIV

Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV.

8 Mar 2012

Doctors identify promising new treatment for hypophosphatasia

Doctors at Washington University School of Medicine in St. Louis, working with Shriners Hospital for Children and other institutions, have identified a promising new treatment for a rare and sometimes life-threatening bone disorder that can affect infants and young children.

8 Mar 2012

Researchers identify key molecular player in mouse model of kidney disease

In findings that may lead to clinical trials of a promising new drug for kidney disease, researchers at Beth Israel Deaconess Medical Center (BIDMC) and their colleagues have identified a key molecular player and shown how a targeted experimental drug can reverse kidney damage in mouse models of diabetes, high blood pressure, genetic kidney disease, and other kidney injuries.

8 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

People with tinnitus can benefit from internet-based therapy

Those suffering from nagging tinnitus can benefit from internet-based therapy just as much as patients who take part in group therapy sessions. These are the findings of a German-Swedish study in which patients with moderate to severe tinnitus tried out various forms of therapy over a ten-week period.

8 Mar 2012

First 'theranostic' agent for treatment of ALL

A team of researchers at Case Western Reserve University School of Medicine has developed the first "theranostic" agent for the treatment of acute lymphoblastic leukemia (ALL).

8 Mar 2012

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

AMTR soon after failure of AEDs may reduce risk of seizures in epilepsy patients

Patients with epilepsy who underwent brain surgery soon after failing to respond to drug treatment, but who also continued to receive drug therapy, had a lower risk of seizures during the 2nd year of follow-up compared to patients who received drug treatment alone, according to a study in the March 7 issue of JAMA.

7 Mar 2012

Heroes of Military Medicine award recipients to be honored on May 2, 2012

The Center for Public-Private Partnerships at The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. is pleased to announce the recipients of the 2012 Heroes of Military Medicine awards.

7 Mar 2012

Physicians study human stem cell use as possible treatment for ischemic stroke

Physicians at the Methodist Neurological Institute are studying the use of human stem cells as a possible treatment for acute ischemic stroke, a leading cause of death and disability. Each year, stroke affects more than 15 million people around the world.

7 Mar 2012

Ivabradine could save thousands of heart failure patients

Researchers behind a major trial of Procoralan believe the pill could save 10,000 lives a year in Britain alone. Ivabradine works by slowing the beating of the heart, helping it to pump blood more efficiently.

7 Mar 2012